Tracking immune system recovery after stem cell transplant for acute lymphoblastic leukemia
Studies how the immune system recovers after stem cell transplant for acute lymphoblastic leukemia.
Plain-language title generated from the registry record
Registry title: Establishment of a Novel Flow Cytometric Diagnostic Assay to Effectively Evaluate Immune Reconstitution After Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia
Key facts
- Where
- Monza and Padova, ItalySee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- What type of cancer has the patient been diagnosed with?
- Has the patient had Down syndrome (an extra copy of chromosome 21) diagnosed?
Source: NCT07899840, who can take part
Where in Italy
- Fondazione IRCCS San Gerardo dei TintoriMonza, ItalyTaking people
- Azienda Ospedaliera Università PadovaPadova, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
- Trial code
- NCT07899840
- Record updated
- 28 October 2026
- Original description
Primary ObjectiveRead full original descriptionShow less
Establishment of a Novel Flow Cytometric Diagnostic Assay to Effectively Evaluate Immune Reconstitution After Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia
Primary Objective
To assess immune reconstitution during the first 18 months following hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia (ALL), with a particular focus on the T-cell compartment (thymic regeneration and surrogate markers of cytotoxic function), using a dedicated panel developed within the EuroFlow consortium.
Secondary Objectives
To assess the impact of donor and recipient characteristics, graft-versus-host disease (GvHD) prophylaxis, and conditioning regimen on post-transplant immune reconstitution.
To evaluate the correlation between immune reconstitution and the development of complications using unsupervised analysis.
Inclusion: Patients who undergo first HSCT for ALL; Signing of informed consent by the patient (age>18) or by parent/legal guardian (age <18).
Exclusion: ALL with specific genetic backgrounds which may impact on IR such as Down syndrome; Lack of informed consent; >1° HSCT.